AAVP-TNF-α

AAVP-TNF-α is a **targeted gene therapy** drug that utilizes a hybrid adeno-associated virus/phage (AAVP) vector engineered for specific delivery of the tumor necrosis factor-α (TNF-α) gene to tumor vasculature[1][2]. Once administered, the vector infects tumor endothelial cells and expresses TNF-α locally, inducing apoptosis and necrosis of tumor blood vessels with minimal systemic toxicity[1][2]. This approach is primarily developed for **antivascular therapy of cancer**, notably melanoma, and potentially other solid tumors. The mechanism of action centers on targeted induction of apoptosis in tumor vasculature, leading to inhibition of tumor growth[1][2]. The strategy aims to overcome traditional limitations of systemic TNF-α therapy, which is otherwise too toxic for clinical use due to widespread cytokine activity[1].

Other names

AAVP-TNF-αadeno-associated virus phage-TNF-αtargeted AAVP vector expressing TNF-α